Cite
HARVARD Citation
Khan, N. et al. (2021). The Efficacy and Safety of Switching From Originator Infliximab to Single or Double Switch Biosimilar Among a Nationwide Cohort of Inflammatory Bowel Disease Patients. Crohn's & colitis 360. 3 (2), p. . [Online].